{"id":40246,"date":"2017-09-01T08:24:51","date_gmt":"2017-09-01T12:24:51","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=40246"},"modified":"2017-09-01T08:24:52","modified_gmt":"2017-09-01T12:24:52","slug":"the-progress-of-immunomedics-inc-nasdaqimmu-in-phase-ii-cancer-study-is-encouraging","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/the-progress-of-immunomedics-inc-nasdaqimmu-in-phase-ii-cancer-study-is-encouraging-40246","title":{"rendered":"The Progress Of Immunomedics, Inc (NASDAQ:IMMU) In Phase II Cancer Study Is Encouraging"},"content":{"rendered":"

The stock of Immunomedics, Inc (NASDAQ:IMMU) <\/strong>closed at $12.64 gaining 7.21% in yesterday\u2019s trading session. This provider made an announcement regarding the encouraging interim results from labetuzumab govitecan (IMMU-130).<\/p>\n

In the heavily-pretreated patients with metastatic colorectal cancer (mCRC), this candidate will be evaluated as a single agent.<\/p>\n

On Aug 21, the provider\u2019s shares closed 7% higher and that was after the announcement of the news. So far this year, the shares of the company have returned 145.5%, which is indeed an over-performance in the industry which gained 5.2% in that period.<\/p>\n

The once weekly 8mg or 10 mg dose of IMMU-30 for those persons that received Pfizer Inc\u2019s PFE Camptosar therapy is what the study is embarking on at the moment and it hopes to carry out a proper evaluation within a short period of time.<\/p>\n

The median progression free survival (PFS) arrived at was 3.6 months for 10 mg and 4.6 months for 8mg dosage. Asides from that, the median overall survivals (OS) showcased by the candidate was\u00a06.4 months (10mg) and 7.5 months (8mg).<\/p>\n

Bayer AG\u2019s BAYRY Stivarga had earlier administered treatment to a subset of 23 patients. In this particular subset, the median OS and PFS achieved by the candidate were 4 months and 6.7 months, respectively. That was a lot much better than Stivarga\u2019s OS and PFS.<\/p>\n

Sacituzumab govitecan (IMMU-132) is the other ADC that the provider is developing for patients with relapsed\/refractive, metastatic triple-negative breast cancer. The company is reminding all its investors on the great need for them to understand that IMMU-132 enjoys Breakthrough Therapy Designation in the U.S.\u00a0At the moment, it has plans underway to file a Biologics License Application.<\/p>\n

The main reason behind the development of IMMU-132 was to help treat a wide array of the metastatic solid tumors. There is also an ongoing evaluation of the IMMU-140, another ADC candidate for the liquid and solid cancers.<\/p>\n

The company\u2019s spokesperson opined<\/a>, \u201cImmunomedicas is committed to delivering to stockholders the significant value created by a number of agreements that it has signed into lately.\u201d<\/p>\n","protected":false},"excerpt":{"rendered":"

The stock of Immunomedics, Inc (NASDAQ:IMMU) closed at $12.64 gaining 7.21% in yesterday\u2019s trading session. This provider made an announcement regarding the encouraging interim results […]<\/p>\n","protected":false},"author":32,"featured_media":40253,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[12849,4859,4860],"stock_ticker":[],"class_list":["post-40246","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-immunomedics-inc","tag-immunomedics-inc-nasdaqimmu","tag-nasdaqimmu","entry"],"acf":[],"yoast_head":"\nThe Progress Of Immunomedics, Inc (NASDAQ:IMMU) In Phase II Cancer Study Is Encouraging - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/the-progress-of-immunomedics-inc-nasdaqimmu-in-phase-ii-cancer-study-is-encouraging-40246\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"The Progress Of Immunomedics, Inc (NASDAQ:IMMU) In Phase II Cancer Study Is Encouraging - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"The stock of Immunomedics, Inc (NASDAQ:IMMU) closed at $12.64 gaining 7.21% in yesterday\u2019s trading session. This provider made an announcement regarding the encouraging interim results […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/the-progress-of-immunomedics-inc-nasdaqimmu-in-phase-ii-cancer-study-is-encouraging-40246\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2017-09-01T12:24:51+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2017-09-01T12:24:52+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/09\/40252-960x0.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"960\" \/>\n\t<meta property=\"og:image:height\" content=\"639\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Greg Folin\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Greg Folin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/the-progress-of-immunomedics-inc-nasdaqimmu-in-phase-ii-cancer-study-is-encouraging-40246#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/the-progress-of-immunomedics-inc-nasdaqimmu-in-phase-ii-cancer-study-is-encouraging-40246\"},\"author\":{\"name\":\"Greg Folin\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e\"},\"headline\":\"The Progress Of Immunomedics, Inc (NASDAQ:IMMU) In Phase II Cancer Study Is Encouraging\",\"datePublished\":\"2017-09-01T12:24:51+00:00\",\"dateModified\":\"2017-09-01T12:24:52+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/the-progress-of-immunomedics-inc-nasdaqimmu-in-phase-ii-cancer-study-is-encouraging-40246\"},\"wordCount\":350,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/the-progress-of-immunomedics-inc-nasdaqimmu-in-phase-ii-cancer-study-is-encouraging-40246#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/09\/40252-960x0.jpg\",\"keywords\":[\"Immunomedics Inc\",\"Immunomedics Inc. (NASDAQ:IMMU)\",\"NASDAQ:IMMU\"],\"articleSection\":[\"Health\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/the-progress-of-immunomedics-inc-nasdaqimmu-in-phase-ii-cancer-study-is-encouraging-40246#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/the-progress-of-immunomedics-inc-nasdaqimmu-in-phase-ii-cancer-study-is-encouraging-40246\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/the-progress-of-immunomedics-inc-nasdaqimmu-in-phase-ii-cancer-study-is-encouraging-40246\",\"name\":\"The Progress Of Immunomedics, Inc (NASDAQ:IMMU) In Phase II Cancer Study Is Encouraging - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/the-progress-of-immunomedics-inc-nasdaqimmu-in-phase-ii-cancer-study-is-encouraging-40246#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/the-progress-of-immunomedics-inc-nasdaqimmu-in-phase-ii-cancer-study-is-encouraging-40246#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/09\/40252-960x0.jpg\",\"datePublished\":\"2017-09-01T12:24:51+00:00\",\"dateModified\":\"2017-09-01T12:24:52+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/the-progress-of-immunomedics-inc-nasdaqimmu-in-phase-ii-cancer-study-is-encouraging-40246#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/the-progress-of-immunomedics-inc-nasdaqimmu-in-phase-ii-cancer-study-is-encouraging-40246\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/the-progress-of-immunomedics-inc-nasdaqimmu-in-phase-ii-cancer-study-is-encouraging-40246#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/09\/40252-960x0.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/09\/40252-960x0.jpg\",\"width\":960,\"height\":639},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/the-progress-of-immunomedics-inc-nasdaqimmu-in-phase-ii-cancer-study-is-encouraging-40246#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"The Progress Of Immunomedics, Inc (NASDAQ:IMMU) In Phase II Cancer Study Is Encouraging\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e\",\"name\":\"Greg Folin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg\",\"caption\":\"Greg Folin\"},\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/greg-folin\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"The Progress Of Immunomedics, Inc (NASDAQ:IMMU) In Phase II Cancer Study Is Encouraging - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/the-progress-of-immunomedics-inc-nasdaqimmu-in-phase-ii-cancer-study-is-encouraging-40246","og_locale":"en_US","og_type":"article","og_title":"The Progress Of Immunomedics, Inc (NASDAQ:IMMU) In Phase II Cancer Study Is Encouraging - Wall Street PR","og_description":"The stock of Immunomedics, Inc (NASDAQ:IMMU) closed at $12.64 gaining 7.21% in yesterday\u2019s trading session. This provider made an announcement regarding the encouraging interim results […]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/the-progress-of-immunomedics-inc-nasdaqimmu-in-phase-ii-cancer-study-is-encouraging-40246","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2017-09-01T12:24:51+00:00","article_modified_time":"2017-09-01T12:24:52+00:00","og_image":[{"width":960,"height":639,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/09\/40252-960x0.jpg","type":"image\/jpeg"}],"author":"Greg Folin","twitter_misc":{"Written by":"Greg Folin","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/the-progress-of-immunomedics-inc-nasdaqimmu-in-phase-ii-cancer-study-is-encouraging-40246#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/the-progress-of-immunomedics-inc-nasdaqimmu-in-phase-ii-cancer-study-is-encouraging-40246"},"author":{"name":"Greg Folin","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e"},"headline":"The Progress Of Immunomedics, Inc (NASDAQ:IMMU) In Phase II Cancer Study Is Encouraging","datePublished":"2017-09-01T12:24:51+00:00","dateModified":"2017-09-01T12:24:52+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/the-progress-of-immunomedics-inc-nasdaqimmu-in-phase-ii-cancer-study-is-encouraging-40246"},"wordCount":350,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/the-progress-of-immunomedics-inc-nasdaqimmu-in-phase-ii-cancer-study-is-encouraging-40246#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/09\/40252-960x0.jpg","keywords":["Immunomedics Inc","Immunomedics Inc. (NASDAQ:IMMU)","NASDAQ:IMMU"],"articleSection":["Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/the-progress-of-immunomedics-inc-nasdaqimmu-in-phase-ii-cancer-study-is-encouraging-40246#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/the-progress-of-immunomedics-inc-nasdaqimmu-in-phase-ii-cancer-study-is-encouraging-40246","url":"https:\/\/cablemanpro.com\/wallstreetpr\/the-progress-of-immunomedics-inc-nasdaqimmu-in-phase-ii-cancer-study-is-encouraging-40246","name":"The Progress Of Immunomedics, Inc (NASDAQ:IMMU) In Phase II Cancer Study Is Encouraging - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/the-progress-of-immunomedics-inc-nasdaqimmu-in-phase-ii-cancer-study-is-encouraging-40246#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/the-progress-of-immunomedics-inc-nasdaqimmu-in-phase-ii-cancer-study-is-encouraging-40246#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/09\/40252-960x0.jpg","datePublished":"2017-09-01T12:24:51+00:00","dateModified":"2017-09-01T12:24:52+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/the-progress-of-immunomedics-inc-nasdaqimmu-in-phase-ii-cancer-study-is-encouraging-40246#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/the-progress-of-immunomedics-inc-nasdaqimmu-in-phase-ii-cancer-study-is-encouraging-40246"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/the-progress-of-immunomedics-inc-nasdaqimmu-in-phase-ii-cancer-study-is-encouraging-40246#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/09\/40252-960x0.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/09\/40252-960x0.jpg","width":960,"height":639},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/the-progress-of-immunomedics-inc-nasdaqimmu-in-phase-ii-cancer-study-is-encouraging-40246#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"The Progress Of Immunomedics, Inc (NASDAQ:IMMU) In Phase II Cancer Study Is Encouraging"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e","name":"Greg Folin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg","caption":"Greg Folin"},"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/greg-folin"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/40246","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/32"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=40246"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/40246\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/40253"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=40246"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=40246"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=40246"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=40246"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}